Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Feasibility and efficacy of daratumumab-vcd in transplant-ineligible elderly patients with newly diagnosed multiple myeloma: First results from the multicenter GMMG-dada study

Blood (2025) 146 (Supplement 1): 4050.

https://doi.org/10.1182/blood-2025-4050

Published: 2025

Journal Articles

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Ute Hegenbart, Niklas Fuhr, Laura Huber, Christoph Kimmich, Kaya Veelken, Tobias Dittrich, Rita Ziehl, Fabian aus dem Siepen, Alexander Carpinteiro, Timon Hansen, Carsten Müller-Tidow, Axel Benner, Stefan Schönland

Blood (2021) 138 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2021-152713

Published: 2021

Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Blood (2020) 135 (18): 1517–1530.

https://doi.org/10.1182/blood.2019003633

Published: 2020

Includes: Supplemental data

Journal Articles

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Sandy W. Wong, MD, Giovanni Palladini, MD PhD, Ute Hegenbart, MD, Heather Landau, MD, Melissa Warner, BS, Arnaud Jaccard, MD PhD, Herve Avet-Loiseau, Timon Hansen, MD, Joan Bladé, MD, María Teresa Cibeira, MD, Efstathios Kastritis, MD, Stefan Schönland, MD, Raymond L. Comenzo, MD

Blood (2015) 126 (23): 3049.

https://doi.org/10.1182/blood.V126.23.3049.3049

Published: 2015

Journal Articles

Translocation t(4;14) Is Not an Adverse Prognostic Factor in Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation.

Timon Hansen, Georgia Schilling, Avichai Shimoni, Jose-Antonio Simon-Perez, Wolfgang Bethge, Peter Liebisch, Rainer Schwerdtfeger, Martin Bornhaeuser, Svenja Otterstetter, Francis Ayuk, Carsten Bokemeyer, Axel R. Zander, Jesus San-Miguel, Arnon Nagler, Nicolaus Kroeger

Blood (2007) 110 (11): 4743.

https://doi.org/10.1182/blood.V110.11.4743.4743

Published: 2007

Journal Articles

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Timon Hansen, Georgia Schilling, MD, Peter Liebisch, MD, Rainer Schwerdtfeger, PD, Jose Antonio Perez-Simon, MD, Martin Bornhaeuser, PD, Svenja Otterstetter, Judith Dierlamm, PD, Arnon Nagler, Dieter Kurt Hossfeld, Carsten Bokemeyer, Axel R. Zander, Nicolaus Kroeger, PD

Blood (2006) 108 (11): 5038.

https://doi.org/10.1182/blood.V108.11.5038.5038

Published: 2006

Journal Articles

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Georgia Schilling, MD, Timon Hansen, Jose Antonio Perez-Simon, MD, Rainer Schwerdtfeger, MD, Martin Bornhaeuser, MD, Svenja Otterstetter, Doris Seeger, Judith Dierlamm, PD, Francis Ayuk, MD, Hossfeld Dieter Kurt, Bokemeyer Carsten, Zander R. Axel, Kroeger Nicolaus, PD

Blood (2005) 106 (11): 4338.

https://doi.org/10.1182/blood.V106.11.4338.4338

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Feasibility and efficacy of daratumumab-vcd in transplant-ineligible elderly patients with newly diagnosed multiple myeloma: First results from the multicenter GMMG-dada study

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Translocation t(4;14) Is Not an Adverse Prognostic Factor in Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation.

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Feasibility and efficacy of daratumumab-vcd in transplant-ineligible elderly patients with newly diagnosed multiple myeloma: First results from the multicenter GMMG-dada study

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Translocation t(4;14) Is Not an Adverse Prognostic Factor in Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation.

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only